Phcog.Net logo
Submit

BROWSE ALL JOURNALS

    SEE ALL 6 JOURNALS
    Pharmacognosy MagazineNOW IN
    Article

    Commigileadin A: A New Triterpenoid from Commiphora gileadensis Aerial Parts

    Hossam M. Abdallah1,2, Gamal A. Mohamed1★, Sabrin R. M. Ibrahim3,4, Abdulrahman E. Koshak1, Ibrahim Alnashri1, Abdullah Alghamdi1, Abdulghani Aljohani1, Abdulrahman Khairy1★ Corresponding author

    1. 1Department of Natural Products and Alternative Medicine, Faculty of Pharmacy, King Abdulaziz University, Jeddah, Saudi Arabia
    2. 2Department of Pharmacognosy, Faculty of Pharmacy, Cairo University, Cairo, Egypt
    3. 3Department of Chemistry, Preparatory Year Program, Batterjee Medical College, Jeddah, Saudi Arabia
    4. 4Department of Pharmacognosy, Faculty of Pharmacy, Assiut University, Assiut, Egypt

    CORRESPONDENCE

    Gamal A. Mohamed

    Department of Natural Products and Alternative Medicine, Faculty of Pharmacy, King Abdulaziz University, Jeddah - 21589, Saudi Arabia.

    gamals2001@yahoo.com

    Received: 17-03-2021; Revised: 19-02-2022; Accepted: 11-03-2022.

    Volume 18, Issue 78 · pp. 256–260 · PUBLISHED 7 July 2022 · DOI: 10.4103/pm.pm_118_21

    View on Pharmacogn. Mag. original site ↗

    ABSTRACT

    Background: Genus Commiphora (Burseraceae) includes about 150 species of aromatic shrubs located in Africa, India, and the Arabian region. C. gileadensis L. has been used for treating several ailments such as constipation, urinary retention, headache, jaundice, joint pain, liver and stomach diseases, and inflammatory disorders. Objectives: In this work, a phytochemical investigation of C. gileadensis aerial parts was carried out. Moreover, the antimicrobial potential of the new metabolite was assessed. Materials and Methods: The aerial parts were extracted at room temperature with methanol (MeOH). The MeOH extract was subjected to various chromatographic techniques to separate the bio‑constituents. Their structures were exhaustively specified by utilizing diversified spectroscopic data and comparing them with the literature. The antimicrobial potential of the new compound 1 was assessed toward Bacillus cereus, Escherichia coli, Staphylococcus aureus, and Clostridium albicans. Results: A new friedelan triterpenoid, commigileadin A [3,11‑dioxo‑(D: A)‑friedo‑olean‑27‑al] (1) and four known metabolites, namely, Stigmasterol (2), naringenin (3), naringenin‑4‑methyl ether (4), and kaempferol (5) were obtained. Compound 1 possessed moderate activity toward B. cereus (inhibition zone diameter (IZD): 12.6 mm and minimum inhibitory concentration [MIC]: 8.9 µg/mL) in comparison to ciprofloxacin (IZD: 21.1 mm and MIC: 2.5 µg/mL, respectively). Conclusion: This work reported the characterization of a new triterpenoid (1) and four known constituents (2–5). Compound 1 possessed a moderate activity toward B. cereus.

    KEYWORDS

    Open in new tab

    REFERENCES

    As published

    Showing references and in-text citations exactly as published.

      Cite this article

      SELECT FORMAT

      Abdallah, H. M., Mohamed, G. A., Ibrahim, S. R. M., Koshak, A. E., Alnashri, I., Alghamdi, A., Aljohani, A., & Khairy, A. (2022). Commigileadin A: A New Triterpenoid from Commiphora gileadensis Aerial Parts. Pharmacognosy Magazine, 18(78), 256–260. https://doi.org/10.4103/pm.pm_118_21